The role of JAK2 abnormalities in hematologic neoplasms.
In 2005, an activating mutation in the Janus kinase 2 (JAK2) was identified in a significant proportion of patients with myeloproliferative neoplasms, mainly polycythemia vera, essential thrombocythemia and primary myelofibrosis. Many types of mutations in the JAK-STAT pathway have been identified,...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2009-07-01
|
Series: | Hematology Reports |
Subjects: | |
Online Access: | http://www.pagepress.org/journals/index.php/hr/article/view/176 |
id |
doaj-8a4df77664954b7eb6d19b4469ade3d2 |
---|---|
record_format |
Article |
spelling |
doaj-8a4df77664954b7eb6d19b4469ade3d22020-11-25T03:53:41ZengPAGEPress PublicationsHematology Reports2038-83222038-83302009-07-0111e10e1010.4081/hr.2009.e10735The role of JAK2 abnormalities in hematologic neoplasms.Mohammed Khalid Alabdulaali0MOHIn 2005, an activating mutation in the Janus kinase 2 (JAK2) was identified in a significant proportion of patients with myeloproliferative neoplasms, mainly polycythemia vera, essential thrombocythemia and primary myelofibrosis. Many types of mutations in the JAK-STAT pathway have been identified, the majority are related to JAK2. Currently JAK2 mutations are important in the area of diagnosis of myeloid neoplasms, but its role beyond the confirmation of clonality is growing and widening our knowledge about these disorders. In addition to that, clinical trials to target JAK2-STAT pathway will widen our knowledge and hopefully will offer more therapeutic options. In this review, we will discuss the role of JAK2 abnormalities in the pathogenesis, diagnosis, classification, severity and management of hematologic neoplasms.http://www.pagepress.org/journals/index.php/hr/article/view/176JAK2Myeloproliferative neoplasmsLeukaemia |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mohammed Khalid Alabdulaali |
spellingShingle |
Mohammed Khalid Alabdulaali The role of JAK2 abnormalities in hematologic neoplasms. Hematology Reports JAK2 Myeloproliferative neoplasms Leukaemia |
author_facet |
Mohammed Khalid Alabdulaali |
author_sort |
Mohammed Khalid Alabdulaali |
title |
The role of JAK2 abnormalities in hematologic neoplasms. |
title_short |
The role of JAK2 abnormalities in hematologic neoplasms. |
title_full |
The role of JAK2 abnormalities in hematologic neoplasms. |
title_fullStr |
The role of JAK2 abnormalities in hematologic neoplasms. |
title_full_unstemmed |
The role of JAK2 abnormalities in hematologic neoplasms. |
title_sort |
role of jak2 abnormalities in hematologic neoplasms. |
publisher |
PAGEPress Publications |
series |
Hematology Reports |
issn |
2038-8322 2038-8330 |
publishDate |
2009-07-01 |
description |
In 2005, an activating mutation in the Janus kinase 2 (JAK2) was identified in a significant proportion of patients with myeloproliferative neoplasms, mainly polycythemia vera, essential thrombocythemia and primary myelofibrosis. Many types of mutations in the JAK-STAT pathway have been identified, the majority are related to JAK2. Currently JAK2 mutations are important in the area of diagnosis of myeloid neoplasms, but its role beyond the confirmation of clonality is growing and widening our knowledge about these disorders. In addition to that, clinical trials to target JAK2-STAT pathway will widen our knowledge and hopefully will offer more therapeutic options. In this review, we will discuss the role of JAK2 abnormalities in the pathogenesis, diagnosis, classification, severity and management of hematologic neoplasms. |
topic |
JAK2 Myeloproliferative neoplasms Leukaemia |
url |
http://www.pagepress.org/journals/index.php/hr/article/view/176 |
work_keys_str_mv |
AT mohammedkhalidalabdulaali theroleofjak2abnormalitiesinhematologicneoplasms AT mohammedkhalidalabdulaali roleofjak2abnormalitiesinhematologicneoplasms |
_version_ |
1724477379238166528 |